Remestemcel-L – Investigational Allogeneic Stem Cell Therapy
Generic Name: Remestemcel-L | Brand Names: TEMCELL® (Japan), Ryoncil™ (proposed US) | Developer: Mesoblast Limited
Overview
Remestemcel-L is an investigational allogeneic (donor-derived) mesenchymal stem cell therapy developed by Mesoblast Limited for the treatment of inflammatory and immune-mediated diseases. It is approved in Japan as TEMCELL® for acute graft-versus-host disease (aGVHD) and is under regulatory review in the United States for the same indication. The therapy is also being investigated for COVID-19 acute respiratory distress syndrome (ARDS) and other inflammatory conditions.
Key Facts
- Developer: Mesoblast Limited (ASX: MSB, NASDAQ: MESO)
- Drug Class: Allogeneic mesenchymal stem cell (MSC) therapy
- Cell Source: Bone marrow-derived mesenchymal lineage precursor cells from healthy adult donors
- Mechanism: Immunomodulation, anti-inflammation, tissue repair
- Administration: Intravenous (IV) infusion
- Status:
- Approved: Japan (TEMCELL®, 2015) for steroid-refractory acute GVHD
- Under Review: United States (BLA submitted to FDA for pediatric steroid-refractory aGVHD)
- Clinical Development: Phase III completed for COVID-19 ARDS
Technology & Mechanism of Action
Cell Type: Mesenchymal Stem Cells (MSCs)
What are MSCs?
- Definition: Multipotent stromal cells that can differentiate into bone, cartilage, fat, and other connective tissues
- Source (Remestemcel-L): Bone marrow aspirate from healthy adult donors
- Allogeneic: “Off-the-shelf” cells from donors (not patient-specific)
- Immune-privileged: Low expression of MHC Class II; do not require HLA matching
- Scalability: Single donor can provide cells for thousands of patient doses
Manufacturing Process
- Donor selection: Healthy adults screened for infectious diseases, genetic disorders
- Bone marrow harvest: Bone marrow aspirate collected from donor
- Cell isolation: Mesenchymal stem cells isolated and purified
- Expansion: Cells cultured in bioreactors with growth media (historically fetal bovine serum; moving to serum-free)
- Quality control: Identity, purity, potency, sterility testing
- Cryopreservation: Cells frozen in cryoprotectant (DMSO) and stored in liquid nitrogen (-150°C to -196°C)
- Thawing & administration: Thawed at bedside immediately before IV infusion
Mechanisms of Action
1. Immunomodulation
- T-cell suppression: Inhibit proliferation and activation of effector T-cells (CD4+, CD8+)
- Regulatory T-cell (Treg) induction: Promote expansion of Tregs that dampen immune responses
- B-cell modulation: Suppress antibody production and B-cell activation
- Dendritic cell modulation: Shift dendritic cells toward tolerogenic phenotype
- Result: “Reset” overactive immune system without causing global immunosuppression
2. Anti-Inflammatory
- Cytokine modulation:
- Reduce pro-inflammatory cytokines: TNF-α, IFN-γ, IL-1β, IL-6, IL-17
- Increase anti-inflammatory cytokines: IL-10, TGF-β
- Prostaglandin E2 (PGE2) secretion: Potent anti-inflammatory mediator
- Indoleamine 2,3-dioxygenase (IDO) production: Suppresses T-cell proliferation
- Result: Reduce cytokine storm and systemic inflammation
3. Tissue Repair & Regeneration
- Growth factor secretion: VEGF, HGF, IGF-1, FGF promote tissue healing
- Extracellular vesicles (EVs): MSCs release EVs containing proteins, mRNAs, microRNAs that promote repair
- Angiogenesis: Promote new blood vessel formation
- Anti-apoptotic: Prevent cell death in damaged tissues
- Result: Accelerate healing of damaged organs (skin, liver, GI tract, lungs)
4. Homing & Trafficking
- Chemokine receptors: MSCs express receptors (CXCR4, CCR2, etc.) that guide them to sites of inflammation
- Homing: After IV infusion, MSCs migrate to inflamed/damaged tissues
- Paracrine effects: MSCs exert therapeutic effects primarily through secreted factors (not engraftment/differentiation)
- Transient presence: MSCs cleared from body within days to weeks (no long-term engraftment)
Clinical Development Programs
1. Acute Graft-Versus-Host Disease (aGVHD)
Disease Background
- Definition: Life-threatening complication of allogeneic bone marrow/stem cell transplantation
- Mechanism: Donor immune cells attack recipient’s tissues (skin, liver, GI tract)
- Incidence: 30–50% of transplant patients develop aGVHD
- Steroid-refractory aGVHD: 30–50% do not respond to first-line corticosteroids; high mortality (30–50% within 100 days)
Clinical Trials
Phase III Trial (Pediatric, US/Canada/Australia)
- Design: Randomized, open-label, multicenter trial
- Population: Pediatric patients (<18 years) with steroid-refractory aGVHD (Grade B-D)
- Intervention:
- Remestemcel-L: 2 million cells/kg IV, twice weekly for 4 weeks (8 infusions) + best available therapy (BAT)
- Control: Best available therapy alone (immunosuppressants, anti-TNF agents, etc.)
- Primary endpoint: Overall response rate (ORR) at Day 28 (complete response + partial response)
Results (Published 2020)
- Overall response rate (ORR):
- Remestemcel-L: 65% (CR + PR)
- Control: 23%
- Statistical significance: p<0.001 (highly significant)
- Complete response (CR): 45% (remestemcel-L) vs 7% (control)
- 100-day survival: 82% (remestemcel-L) vs 39% (control) – dramatic improvement
- Organ-specific responses:
- Durability: Responses sustained at 6 months and 1 year in majority of responders
Safety
- Adverse events: Similar between remestemcel-L and control groups
- Infusion reactions: Mild (fever, chills) in <10%; no severe reactions
- Infections: No increase vs control (MSCs do not cause immunosuppression)
- Ectopic tissue/tumors: None observed
- Overall: Well-tolerated; favorable safety profile
Regulatory Status
Japan (Approved)
- Brand name: TEMCELL® HS Inj.
- Approval date: September 2015
- Indication: Steroid-refractory aGVHD (pediatric and adult)
- Marketer: JCR Pharmaceuticals (exclusive license)
- Sales: ¥1.5–2.0B annually (~US$14–18M)
United States (Under Review)
- Proposed brand name: Ryoncil™
- BLA submission: November 2020 (Biologics License Application to FDA)
- FDA review:
- Complete Response Letter (CRL) #1: October 2020 – CMC (Chemistry, Manufacturing, Controls) issues; potency assay concerns
- Resubmission: June 2023 (additional manufacturing data, potency assay validation)
- Complete Response Letter (CRL) #2: September 2023 – FDA requested additional information on potency assay and clinical data interpretation
- Current status: Mesoblast addressing FDA concerns; ongoing dialogue
- Designations:
- Orphan Drug Designation: Granted (expedited review, 7-year market exclusivity if approved)
- Pediatric Rare Disease Designation: Granted (Priority Review Voucher if approved – worth $100M+)
- Timeline: Approval uncertain; potential 2024–2025 if FDA satisfied with responses
Europe
- Status: Not yet submitted; Mesoblast prioritizing US approval
- Orphan Drug Designation: Granted by EMA
Market Opportunity (US)
- Allogeneic transplants: ~8,000 annually (US)
- aGVHD incidence: ~2,400–4,000 cases
- Steroid-refractory aGVHD: ~1,200–2,000 cases (eligible for remestemcel-L)
- Pricing: Estimated $200,000–400,000 per treatment course (orphan cell therapy)
- Peak sales potential: $300–600 million annually (US pediatric SR-aGVHD)
- Competition: Incyte’s Jakafi® (ruxolitinib, JAK inhibitor) – approved 2019 for SR-aGVHD (oral drug)
2. COVID-19 Acute Respiratory Distress Syndrome (ARDS)
Rationale
- COVID-19 pathophysiology: Severe cases characterized by cytokine storm, lung inflammation, ARDS
- MSC mechanism: Suppress cytokine storm, reduce lung inflammation, promote tissue repair
- Hypothesis: Remestemcel-L could reduce mortality in COVID-19 ARDS patients
Phase III Trial
- Design: Randomized, double-blind, placebo-controlled, multicenter trial
- Population: 222 patients with moderate-to-severe COVID-19 ARDS (requiring mechanical ventilation or high-flow oxygen)
- Intervention:
- Remestemcel-L: 2 million cells/kg IV, 2 infusions (Days 0 and 3) + standard of care
- Placebo: Standard of care alone
- Primary endpoint: 30-day survival
- Trial completion: 2021
Results (Announced 2021)
- Primary endpoint (overall population):
- 30-day survival: Not statistically significant difference between remestemcel-L and placebo
- Reason: Trial enrolled heterogeneous population (mild to severe ARDS); diluted treatment effect
- Prespecified subgroup analysis (moderate-to-severe ARDS):
- Age subgroup (<65 years):
- 30-day survival: 91% (remestemcel-L) vs 73% (placebo) – highly significant
- Safety: Well-tolerated; no serious adverse events attributed to remestemcel-L
Regulatory Path
- FDA: No BLA submitted yet; Mesoblast evaluating regulatory strategy
- Challenge:
- COVID-19 pandemic waning; ARDS market opportunity less urgent
- Primary endpoint not met in overall population (subgroup analysis less compelling to regulators)
- Would need additional trial targeting moderate-to-severe ARDS subgroup
- Status: Program on hold; company prioritizing aGVHD approval and other indications
- Future potential: Could pursue approval for ARDS (non-COVID) if market opportunity justifies investment
Market Opportunity (ARDS, if pursued)
- ARDS incidence: ~200,000 cases annually (US); ~75,000 severe cases
- Mortality: 30–40% (severe ARDS)
- Current treatment: Supportive care (mechanical ventilation, prone positioning); no approved pharmacologic therapy
- Pricing: $50,000–150,000 per treatment course
- Peak sales potential: $500M–1B+ (if approved for ARDS)
- Competition: Limited; mostly supportive care
3. Other Indications (Mesoblast Pipeline)
While remestemcel-L is the aGVHD/ARDS product, Mesoblast has other MSC products (rexlemestrocel-L) for different indications. For completeness:
Chronic Heart Failure (Rexlemestrocel-L, not Remestemcel-L)
- Product: Rexlemestrocel-L (MPC-150-IM) – different formulation/delivery
- Indication: Chronic heart failure with reduced ejection fraction (HFrEF)
- Delivery: Transendocardial injection (catheter-based, directly into heart muscle)
- Status: Phase III DREAM-HF trial ongoing; data expected 2024–2025
Chronic Lower Back Pain (Rexlemestrocel-L, not Remestemcel-L)
- Product: Rexlemestrocel-L (MPC-06-ID)
- Indication: Chronic discogenic lower back pain
- Delivery: Single injection into damaged intervertebral disc
- Status: Phase III completed; partnered with Grünenthal (Europe)
Manufacturing & Quality
Manufacturing Facilities
Mesoblast Facilities
- Melbourne, Australia: R&D and clinical-scale manufacturing
- Singapore (Lonza partnership): Commercial-scale GMP manufacturing facility
- Capacity: Designed to produce tens of thousands of doses annually
JCR Pharmaceuticals (Japan)
- Japan facility: GMP manufacturing for TEMCELL (technology transfer from Mesoblast)
Regulatory Challenges (CMC)
FDA Complete Response Letters (CRLs)
- Issue #1: Potency Assay
- Challenge: FDA requires validated potency assay that predicts clinical efficacy
- Complexity: MSCs have multiple mechanisms of action; difficult to capture in single assay
- Mesoblast approach: Developed multi-parameter potency assay measuring immunomodulatory and anti-inflammatory functions
- Status: Submitted additional validation data to FDA (2023)
- Issue #2: Manufacturing Process Validation
- Challenge: Demonstrate consistency across batches; control critical quality attributes
- Mesoblast approach: Enhanced process controls, additional batch data, improved analytics
- Issue #3: Clinical Data Interpretation
- Challenge: FDA questions about endpoint definitions, statistical analysis
- Mesoblast approach: Provided additional analyses, clarifications
Importance of CMC for Cell Therapies
- Cell therapies are “living drugs” – more complex than small molecules or antibodies
- Batch-to-batch variability inherent to biological systems
- FDA scrutiny high for novel cell therapies (ensuring safety, efficacy, consistency)
- Remestemcel-L CRLs reflect broader industry challenge: establishing robust CMC for allogeneic cell therapies
Competitive Landscape
Acute GVHD Market
Approved Therapies (US)
- First-line: Corticosteroids (methylprednisolone, prednisone) – standard of care
- Second-line (steroid-refractory):
- Incyte’s Jakafi® (ruxolitinib): Approved May 2019 for SR-aGVHD (ages 12+)
- Mechanism: JAK1/JAK2 inhibitor (oral tablet)
- Efficacy: 55% ORR in Phase III trial
- Advantage: Oral administration; established commercial infrastructure
- Sales: ~$500M annually (GVHD indication; Jakafi also approved for myelofibrosis, polycythemia vera)
- Off-label: Immunosuppressants (tacrolimus, mycophenolate), anti-TNF agents (infliximab, etanercept), extracorporeal photopheresis
Remestemcel-L vs Jakafi
- Remestemcel-L advantages:
- ✅ Superior efficacy in pediatrics (65% ORR vs 55% Jakafi; 82% vs 39% survival in trials – though different populations)
- ✅ Novel mechanism (immunomodulation without immunosuppression)
- ✅ No increased infection risk
- ✅ Pediatric Rare Disease Designation (Priority Review Voucher if approved)
- Jakafi advantages:
- ✅ Already approved (first-mover advantage)
- ✅ Oral administration (vs IV infusion for remestemcel-L)
- ✅ Established commercial infrastructure (Incyte sales force)
- ✅ Approved for adults and adolescents (12+); remestemcel-L BLA is pediatric-focused
- Market dynamics: If remestemcel-L approved, likely to coexist with Jakafi; physicians may choose based on patient characteristics, severity, age
Other MSC Therapies
Approved Allogeneic MSC Products (Global)
- TEMCELL® (remestemcel-L, Japan): aGVHD
- Alofisel® (Darvadstrocel, EU): Complex perianal fistulas in Crohn’s disease (Takeda)
- Stemirac® (Japan): Spinal cord injury (Nipro)
- Limited competition: Few approved allogeneic MSC therapies globally; remestemcel-L is leading product for GVHD
Investigational MSC Therapies
- Athersys (MultiStem): Allogeneic stem cells for stroke, ARDS (Phase II/III)
- Pluristem (PLX cells): Placenta-derived cells for critical limb ischemia, muscle injury (Phase III)
- Celularity (CYCART): Placenta-derived allogeneic cells for cancer, infectious disease (Phase I/II)
Investment Considerations
For Mesoblast Shareholders
Bull Case
- ✅ Proven efficacy: 65% ORR, 82% survival in Phase III trial (pediatric SR-aGVHD)
- ✅ Japan approval validates platform: TEMCELL demonstrates regulatory and commercial viability
- ✅ Large US market: $300–600M peak sales potential (pediatric SR-aGVHD)
- ✅ Orphan drug benefits: 7-year exclusivity, Priority Review Voucher (worth $100M+)
- ✅ COVID-19 ARDS data: Positive subgroup results provide optionality for future ARDS indication
- ✅ Unmet need: SR-aGVHD has high mortality; limited treatment options
Bear Case
- ❌ FDA approval uncertainty: Two CRLs indicate significant regulatory hurdles; approval not guaranteed
- ❌ CMC challenges: Manufacturing complexity; potency assay validation ongoing
- ❌ Timeline delays: Approval pushed back multiple times; uncertainty on final timeline
- ❌ Competition: Jakafi already approved; established market presence
- ❌ Financial stress: Mesoblast burning cash (~A$60–100M annually); frequent dilutive capital raises
- ❌ COVID-19 ARDS: Primary endpoint not met; program on hold
Key Catalysts
- FDA approval decision: If/when FDA approves remestemcel-L for pediatric SR-aGVHD (timeline uncertain)
- Commercial launch (US): Revenue ramp, market share vs Jakafi
- Label expansion: Adult SR-aGVHD, first-line aGVHD (if additional trials conducted)
- ARDS indication: If Mesoblast pursues approval for non-COVID ARDS
Valuation Impact
Scenario Analysis (Mesoblast Market Cap)
- Current: ~US$300–500M (depressed due to regulatory uncertainty, cash burn)
- FDA approval (base case): $1–2B (approval de-risks; commercial launch begins)
- Commercial success (bull case): $3–5B+ (strong uptake, label expansions, ARDS approval)
- FDA rejection (bear case): $50–150M (bankruptcy risk; asset fire sale)
Clinical & Real-World Evidence
Published Studies
Key Publications
- Kurtzberg et al. (2020), Biology of Blood and Marrow Transplantation: Phase III pediatric SR-aGVHD trial results
- Hashimoto et al. (2016), International Journal of Hematology: Japan Phase I/II trial (TEMCELL)
- Lanzoni et al. (2021), Stem Cells Translational Medicine: COVID-19 ARDS Phase III trial results
- Multiple case reports: Successful treatment of severe, refractory aGVHD with remestemcel-L/TEMCELL
Real-World Evidence (Japan)
TEMCELL Post-Marketing Surveillance (2015–2024)
- Patients treated: 500+ (cumulative)
- Response rate: Consistent with clinical trials (~60% ORR)
- Survival: 100-day survival ~70% (vs ~30–50% historical controls)
- Safety: No new safety signals; well-tolerated in real-world setting
- Conclusion: Real-world data validates clinical trial results
Future Outlook
Near-Term (2024–2025)
- FDA approval decision: Ongoing review; potential approval if CMC issues resolved
- Commercial preparation: If approved, Mesoblast preparing for US launch (manufacturing scale-up, commercial partnerships)
- Capital raises: Likely additional equity raises to fund commercialization (dilution risk)
Medium-Term (2026–2028)
- US commercial launch: Revenue ramp; market share battle with Jakafi
- Label expansions: Adult SR-aGVHD, first-line aGVHD (if additional trials conducted)
- Europe approval: Potential EMA submission and approval
- ARDS indication: Decision on whether to pursue non-COVID ARDS approval
Long-Term (2029+)
- Market maturity: Established position in aGVHD market
- Next-generation products: Improved manufacturing (serum-free, automated), enhanced potency
- New indications: Chronic GVHD, other inflammatory/immune-mediated diseases
Key Takeaways
- ✅ Proven efficacy: 65% ORR, 82% survival in Phase III pediatric SR-aGVHD trial
- ✅ Approved in Japan (TEMCELL): Validates regulatory pathway and clinical utility
- ✅ Novel mechanism: Immunomodulation without immunosuppression; favorable safety profile
- ✅ Large unmet need: SR-aGVHD has high mortality; limited effective treatments
- ❌ FDA approval uncertain: Two CRLs; CMC challenges ongoing
- ❌ Timeline delays: Approval pushed back multiple times; final timeline unclear
- ❌ Financial risk: Mesoblast burning cash; frequent dilutive capital raises
- ❌ Competition: Jakafi already approved and established in market
Related Terms
- Mesenchymal stem cells (MSCs) – Adult stem cells with immunomodulatory properties
- Allogeneic cell therapy – Donor-derived cells (off-the-shelf)
- Acute graft-versus-host disease (aGVHD) – Complication of bone marrow transplant
- Steroid-refractory – Disease that does not respond to corticosteroid treatment
- ARDS (Acute Respiratory Distress Syndrome) – Severe lung inflammation
- BLA (Biologics License Application) – FDA application for biologic drug approval
- CRL (Complete Response Letter) – FDA letter indicating approval not granted
- CMC (Chemistry, Manufacturing, and Controls) – Regulatory requirements for drug manufacturing
- Potency assay – Test measuring biological activity of cell therapy
- TEMCELL – Brand name for remestemcel-L in Japan
Disclaimer: This information is for educational purposes only and does not constitute medical or investment advice. Remestemcel-L is investigational in most countries (approved only in Japan as TEMCELL). Mesoblast stock is high-risk, speculative investment with significant risks including FDA rejection, financial distress, and dilution. DYOR and consult professionals before making medical or investment decisions.
Mesoblast Investor Relations: investorcentre.mesoblast.com
Clinical Trials: ClinicalTrials.gov (Search: Remestemcel-L)
FDA: www.fda.gov (Search: Remestemcel-L, Mesoblast)
Related Topics: Remestemcel-L, TEMCELL, Mesoblast, Acute GVHD, Mesenchymal Stem Cells, Cell Therapy, Regenerative Medicine, COVID-19 ARDS, Allogeneic Cell Therapy, Orphan Drugs, FDA Approval, Biotech Stocks, Clinical Trials
✨ Support Our Mission ✨
Help us continue building tools that simplify complexity!
Every contribution fuels new features and improvements
Thank you for being part of our journey! 🚀
